<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">CURRENT REPORT FOR ISSUERS SUBJECT TO
THE</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">1934 ACT REPORTING REQUIREMENTS</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Washington, DC 20549</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Pursuant to Section 13 or 15(d) of the
Securities Exchange Act</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report&nbsp;&nbsp;(Date of Earliest
Event Reported): February 29, 2012</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Radient Pharmaceuticals Corporation</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified
in its charter)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; line-height: 115%; text-align: center">Delaware</TD>
    <TD STYLE="width: 34%; line-height: 115%; text-align: center">001-16695</TD>
    <TD STYLE="width: 33%; line-height: 115%; text-align: center">33-0413161</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; text-align: center">(State&nbsp;or&nbsp;other</TD>
    <TD STYLE="line-height: 115%; text-align: center">&nbsp;</TD>
    <TD STYLE="line-height: 115%; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; text-align: center">jurisdiction&nbsp;of</TD>
    <TD STYLE="line-height: 115%; text-align: center">(Commission&nbsp;File&nbsp;Number)</TD>
    <TD STYLE="line-height: 115%; text-align: center">(IRS&nbsp;Employer&nbsp;Identification&nbsp;No.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; text-align: center">incorporation)</TD>
    <TD STYLE="line-height: 115%; text-align: center">&nbsp;</TD>
    <TD STYLE="line-height: 115%; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">2492 Walnut Avenue, Suite 100, Tustin,
California, 92780-7039</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices
(zip code))</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">714-505-4461</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&rsquo;s telephone number,
including area code)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2 below):</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a - 12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13d-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 2.9pt 0 0"><B>Item 7.01 Regulation FD Disclosure. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 5.8pt 0 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As disclosed on the Current Report on
Form 8-K that we filed on February 23, 2012, we are actively seeking financing to improve our working capital shortage. Also as
disclosed in that 8-K, we received a term sheet with a potential investor that contemplates the issuance of an 18 month $3,315,000
convertible note that provides for an initial $250,000 advance and, subject to our satisfaction of certain funding conditions,
entitles us to receive additional advances of up to $2,750,000 over a period of approximately 11 months. Certain of our existing
note holders have the right to participate in such financing. Additionally, now that the Securities and Exchange Commission has
declared our registration statement on Form S-1 effective, we hope that the common stock issuable upon exercise of certain warrants
that was registered therein, will be exercised for cash.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Management intends to submit a letter
to investors providing an update on 2012 business trends and discussing the Company&rsquo;s current outlook for 2012. Management
believes that this additional information is useful to in assessing the Company&rsquo;s historical and future performance. Some
of the additional information contained in the letter would otherwise constitute material non public information; we are filing
this 8-K to disclose such information. The anticipated milestones and other anticipated results contained in the letter, are predicated
on the Company successfully completing the above noted financing(s) and includes the following information:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><I><U>Current Anticipated Milestones
for 2012</U></I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">Continue and expand the Advertising &amp; Outreach
Programs and sales for Onko-Sure<FONT STYLE="color: black">&reg;</FONT> for the U.S. Colorectal Cancer (&ldquo;CRC&rdquo;) market
originally launched in January 2012;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Increase the number of laboratories providing the
Onko-Sure<FONT STYLE="color: black">&reg; CRC test as well as increase the number of physicians ordering the </FONT>Onko-Sure<FONT STYLE="color: black">&reg;
CRC test.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Begin marketing a Clinical Laboratory Improvement
Amendments (&ldquo;CLIA&rdquo;) based Lung Cancer Screening Test in the U.S. during the 2<SUP>nd</SUP> QTR 2012 based upon independent
3<SUP>rd</SUP> Party Clinical Trials completed in 2011 with Onko-Sure&reg; used as a Lung Cancer Screening Test which demonstrated
sensitivity of 65% and specificity of 85%. (For non-small cell lung cancer sensitivity is even higher at 75%.)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">Increase the acceptance of our Lung Cancer Screening
Test in Canada by the end of the 2<SUP>nd</SUP> QTR 2012.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">Commence collaborative clinical study for Ovarian
Cancer in the 2<SUP>nd</SUP> QTR 2012.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">6.</TD><TD STYLE="text-align: justify">Transition our current Onko-Sure<FONT STYLE="color: black"><B>&reg;
</B></FONT><FONT STYLE="color: #1A1A1A">enzyme-linked immunosorbent assay (&ldquo;</FONT>ELISA&rdquo;) test to a multiplex bead
array assay (&ldquo;MBAA&rdquo;) before the end of 2012 to create various new multi-test cancer diagnostics.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>7.</B></TD><TD STYLE="text-align: justify">Continue to present data and scientific conferences
and publish results. In 2012, six abstracts were submitted to high-ranking oncology conferences nationally and internationally;
to date, five out of six have been accepted for presentation. These presentations will provide the Company with direct contact
with influential oncologists and educate them about our products. Furthermore, at each of these conferences, our abstracts will
be published in their corresponding 2012 journals.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">8.</TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Generate
                                                                                  positive cash flow operations by the 4<SUP>th
                                                                                  </SUP>QTR 2012 based upon sales of Onko-Sure<FONT STYLE="color: black">&reg;
                                                                                  and through the sales of our Lung Cancer Screening
                                                                                  Test.</FONT></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>9.</B></TD><TD STYLE="text-align: justify">Assuming
we close the financing described above and all of the warrants that were recently registered are exercised for cash, we could receive up to approximately $3,461,000 over the next 12 months. Additional capital could be raised
this year if additional warrants issued to our 2011 note holders are included in an effective registration statement and are exercised
for cash this year. These funds are critically needed to execute on our business development plans and build shareholder
value.</TD>
</TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 3pt; text-align: center"><I><U>Value Creation &amp;
Building Market Cap</U></I></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><I><U></U></I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">With the capital infusions described above completed,
we will be financially backed by multiple institutional investors committed to funding RXPC which should help remove any remaining
&ldquo;financial viability clouds&rdquo; off of the Company.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Due in part to our advertising and outreach program
started in late January 2012, we anticipate increasing the number of labs selling Onko-Sure&reg; in the U.S. and overseas and
in Canada for Lung Cancer Screening during the second and third quarter of 2012. We are hopeful that this advertising and outreach
program will provide an increase in Onko-Sure&reg; sales for 2012.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">The paramount goal is to gain profitability before
year-end 2012.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">We have had significant publishing and presentation
events during the first quarter and this will continue with 4 more abstracts being presented in the second quarter that will greatly
increase visibility to U.S. physicians and lab directors as to the value of using Onko-Sure&reg;.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">In the near term, we anticipate expanding our U.S.
sales team by at least 2 medical science liaison professionals.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">6.</TD><TD STYLE="text-align: justify">We also believe that we can be in a position by late-2012
to out-license up to 17 separate CLIA based cancer tests through the development of a multiplex bead array assay for various cancer
types using our Onko-Sure&reg; Technology.</TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">The letter also discusses
the lung cancer diagnostic market opportunity based on current information related to lung cancer occurrence, diagnosis and treatment
options that we obtained from various sources. Based on this information, the letter goes on to state that<U> </U>currently, there
is no generally accepted screening test for lunch cancer or regulatory approved blood biomarker for lung cancer screening. <B>
</B>The Company&rsquo;s Lung Cancer Screening Test can fill this gap as it is a low cost blood biomarker test with a good detection
capability and a sensitivity of 65% and specificity of 85% for lung cancer in general. For non-small cell lung cancer sensitivity
is even higher at 75% sensitivity. There have been eight scientific journal publications reporting high sensitivities and specificities
for this first of its kind lung cancer screening test. Finally, the letter states that although there are several imaging techniques
that are currently being used for the detection of lung cancer including: <FONT STYLE="text-underline-style: none; color: windowtext"><I>chest
x-rays</I></FONT>, <FONT STYLE="text-underline-style: none; color: windowtext"><I>spiral (helical) CT scans</I></FONT> and low
dose CT scans, the costs are high and the patient is exposed to harmful x-rays for test sensitivity of between 75-90%. It will
be less costly and faster for the patient to do a blood test, such as Onko-Sure&reg;, and be able to detect lesions even smaller
than 1 cm, that are often missed by the routine first-line lung cancer diagnostic, chest x-ray.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 8.7pt 0 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 8.7pt 0 0; text-align: justify"><B>Safe-Harbor Statement </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 2.9pt 0 0; text-align: justify">This Form 8-K contains forward-looking
statements regarding future events and future performance that involve risks and uncertainties that could materially affect actual
results, including statements regarding financial guidance for first quarter 2012 and full year 2012, our expectations regarding
our Onko-Sure&reg; product and profitability, business development opportunities and expected fees and expenses related to these
business development opportunities. Factors that could cause actual results to vary from current expectations and forward-looking
statements contained in this Form 8-K include, but are not limited to those factors contained in our Securities and Exchange Commission
filings, including the Form 10-K, 10-Q and 8-K reports. As a result, actual results may vary from those contemplated herein and it is possible that some or all of
the events disclosed herein may not ever occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Current Report on Form 8-K is neither
an offer to sell nor the solicitation of an offer to buy our securities or any other securities and shall not constitute an offer
to sell or solicitation of offers to buy any securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="line-height: 115%; font-weight: bold; text-align: justify">RADIENT PHARMACEUTICALS CORPORATION</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; line-height: 115%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 36%; line-height: 115%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; text-align: justify">By:</TD>
    <TD STYLE="border-bottom: black 1pt solid; line-height: 115%; text-align: justify">&nbsp; /s/ Douglas MacLellan</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="line-height: 115%; text-align: justify">Name:&nbsp;&nbsp;Douglas MacLellan</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="line-height: 115%; text-align: justify">Title:&nbsp;&nbsp;&nbsp; Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="line-height: 115%; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">Dated: February 29, 2012</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v304307_8k.htm", "description": "8-K", "secsgml_size_bytes": 27745}]
{"company-data": {"conformed-name": "RADIENT PHARMACEUTICALS Corp", "cik": "0000838879", "assigned-sic": "2834", "irs-number": "330413161", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-16695", "film-number": "12655134"}, "business-address": {"street1": "2492 WALNUT AVENUE", "street2": "STE 100", "city": "TUSTIN", "state": "CA", "zip": "92780", "phone": "7145054460"}, "mail-address": {"street1": "2492 WALNUT AVENUE", "street2": "STE 100", "city": "TUSTIN", "state": "CA", "zip": "92780"}, "former-company": [{"former-conformed-name": "AMDL INC", "date-changed": "19920703"}, {"former-conformed-name": "CALIFORNIA VENTURES INC", "date-changed": "19890905"}]}
CURRENT REPORT FOR ISSUERS SUBJECT TO
THE
1934 ACT REPORTING REQUIREMENTS
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act
Date of Report  (Date of Earliest
Event Reported): February 29, 2012
Radient Pharmaceuticals Corporation
(Exact name of registrant as specified
in its charter)
Delaware
001-16695
33-0413161
(State or other
jurisdiction of
(Commission File Number)
(IRS Employer Identification No.)
incorporation)
2492 Walnut Avenue, Suite 100, Tustin,
California, 92780-7039
(Address of principal executive offices
(zip code))
714-505-4461
(Registrant's telephone number,
including area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2 below):
£
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
£
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a - 12)
£
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
£
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13d-4(c))
Item 7.01 Regulation FD Disclosure.
As disclosed on the Current Report on
Form 8-K that we filed on February 23, 2012, we are actively seeking financing to improve our working capital shortage. Also as
disclosed in that 8-K, we received a term sheet with a potential investor that contemplates the issuance of an 18 month $3,315,000
convertible note that provides for an initial $250,000 advance and, subject to our satisfaction of certain funding conditions,
entitles us to receive additional advances of up to $2,750,000 over a period of approximately 11 months. Certain of our existing
note holders have the right to participate in such financing. Additionally, now that the Securities and Exchange Commission has
declared our registration statement on Form S-1 effective, we hope that the common stock issuable upon exercise of certain warrants
that was registered therein, will be exercised for cash.
Management intends to submit a letter
to investors providing an update on 2012 business trends and discussing the Company's current outlook for 2012. Management
believes that this additional information is useful to in assessing the Company's historical and future performance. Some
of the additional information contained in the letter would otherwise constitute material non public information; we are filing
this 8-K to disclose such information. The anticipated milestones and other anticipated results contained in the letter, are predicated
on the Company successfully completing the above noted financing(s) and includes the following information:
Current Anticipated Milestones
for 2012
1.
Continue and expand the Advertising & Outreach
Programs and sales for Onko-Sure
®
for the U.S. Colorectal Cancer ("CRC") market
originally launched in January 2012;
2.
Increase the number of laboratories providing the
Onko-Sure
® CRC test as well as increase the number of physicians ordering the
Onko-Sure
®
CRC test.
3.
Begin marketing a Clinical Laboratory Improvement
Amendments ("CLIA") based Lung Cancer Screening Test in the U.S. during the 2
nd
QTR 2012 based upon independent
3
rd
Party Clinical Trials completed in 2011 with Onko-Sure® used as a Lung Cancer Screening Test which demonstrated
sensitivity of 65% and specificity of 85%. (For non-small cell lung cancer sensitivity is even higher at 75%.)
4.
Increase the acceptance of our Lung Cancer Screening
Test in Canada by the end of the 2
nd
QTR 2012.
5.
Commence collaborative clinical study for Ovarian
Cancer in the 2
nd
QTR 2012.
6.
Transition our current Onko-Sure
®
enzyme-linked immunosorbent assay ("
ELISA") test to a multiplex bead
array assay ("MBAA") before the end of 2012 to create various new multi-test cancer diagnostics.
7.
Continue to present data and scientific conferences
and publish results. In 2012, six abstracts were submitted to high-ranking oncology conferences nationally and internationally;
to date, five out of six have been accepted for presentation. These presentations will provide the Company with direct contact
with influential oncologists and educate them about our products. Furthermore, at each of these conferences, our abstracts will
be published in their corresponding 2012 journals.
8.
Generate
                                                                                  positive cash flow operations by the 4
th
QTR 2012 based upon sales of Onko-Sure
®
                                                                                  and through the sales of our Lung Cancer Screening
                                                                                  Test.
9.
Assuming
we close the financing described above and all of the warrants that were recently registered are exercised for cash, we could receive up to approximately $3,461,000 over the next 12 months. Additional capital could be raised
this year if additional warrants issued to our 2011 note holders are included in an effective registration statement and are exercised
for cash this year. These funds are critically needed to execute on our business development plans and build shareholder
value.
Value Creation &
Building Market Cap
1.
With the capital infusions described above completed,
we will be financially backed by multiple institutional investors committed to funding RXPC which should help remove any remaining
"financial viability clouds" off of the Company.
2.
Due in part to our advertising and outreach program
started in late January 2012, we anticipate increasing the number of labs selling Onko-Sure® in the U.S. and overseas and
in Canada for Lung Cancer Screening during the second and third quarter of 2012. We are hopeful that this advertising and outreach
program will provide an increase in Onko-Sure® sales for 2012.
3.
The paramount goal is to gain profitability before
year-end 2012.
4.
We have had significant publishing and presentation
events during the first quarter and this will continue with 4 more abstracts being presented in the second quarter that will greatly
increase visibility to U.S. physicians and lab directors as to the value of using Onko-Sure®.
5.
In the near term, we anticipate expanding our U.S.
sales team by at least 2 medical science liaison professionals.
6.
We also believe that we can be in a position by late-2012
to out-license up to 17 separate CLIA based cancer tests through the development of a multiplex bead array assay for various cancer
types using our Onko-Sure® Technology.
The letter also discusses
the lung cancer diagnostic market opportunity based on current information related to lung cancer occurrence, diagnosis and treatment
options that we obtained from various sources. Based on this information, the letter goes on to state that
currently, there
is no generally accepted screening test for lunch cancer or regulatory approved blood biomarker for lung cancer screening.
The Company's Lung Cancer Screening Test can fill this gap as it is a low cost blood biomarker test with a good detection
capability and a sensitivity of 65% and specificity of 85% for lung cancer in general. For non-small cell lung cancer sensitivity
is even higher at 75% sensitivity. There have been eight scientific journal publications reporting high sensitivities and specificities
for this first of its kind lung cancer screening test. Finally, the letter states that although there are several imaging techniques
that are currently being used for the detection of lung cancer including:
chest
x-rays
,
spiral (helical) CT scans
and low
dose CT scans, the costs are high and the patient is exposed to harmful x-rays for test sensitivity of between 75-90%. It will
be less costly and faster for the patient to do a blood test, such as Onko-Sure®, and be able to detect lesions even smaller
than 1 cm, that are often missed by the routine first-line lung cancer diagnostic, chest x-ray.
Safe-Harbor Statement
This Form 8-K contains forward-looking
statements regarding future events and future performance that involve risks and uncertainties that could materially affect actual
results, including statements regarding financial guidance for first quarter 2012 and full year 2012, our expectations regarding
our Onko-Sure® product and profitability, business development opportunities and expected fees and expenses related to these
business development opportunities. Factors that could cause actual results to vary from current expectations and forward-looking
statements contained in this Form 8-K include, but are not limited to those factors contained in our Securities and Exchange Commission
filings, including the Form 10-K, 10-Q and 8-K reports. As a result, actual results may vary from those contemplated herein and it is possible that some or all of
the events disclosed herein may not ever occur.
This Current Report on Form 8-K is neither
an offer to sell nor the solicitation of an offer to buy our securities or any other securities and shall not constitute an offer
to sell or solicitation of offers to buy any securities.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
RADIENT PHARMACEUTICALS CORPORATION
By:
/s/ Douglas MacLellan
Name:  Douglas MacLellan
Title:    Chief Executive Officer
Dated: February 29, 2012